CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,992 enrolled
Drug / intervention
CSL Limited Influenza Virus Vaccine +2 morebiological
Likely dose
CSL Limited Influenza Virus Vaccine 0.25mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00825162
NCT00825162Phase 4Completed
CompareCT.gov

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years

Seqirus·interventional·Posted Jan 19, 2009·Updated May 23, 2018

In Brief

A Phase 4 clinical trial evaluating CSL Limited Influenza Virus Vaccine for Influenza. Completed, enrolled 1,992 participants across 7 sites.

Detailed Summary

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged \>= 6 Months to \< 18 Years

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesAustralia
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2009
Enrollment StartMar 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.5 years ago

Interventions

CSL Limited Influenza Virus Vaccinebiological

Single or two-vaccination regimen (0.25mL)

CSL Limited Influenza Virus Vaccinebiological

Single or two-vaccination regimen (0.5mL)

CSL Limited Influenza Virus Vaccinebiological

Single vaccination regimen (0.5mL)